Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.

Tytuł:
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Autorzy:
Herrmann AB; Institut für Experimentelle Biomedizin II, Universitätsklinikum Würzburg, Würzburg, Germany.
Müller ML; Rudolf-Virchow-Zentrum für Experimentelle Biomedizin I, Universitätsklinikum Würzburg, Würzburg, Germany.
Orth MF; Labor für Pädiatrische Sarkombiologie, Medizinische Fakultät, Pathologisches Institut, LMU München, München, Germany.
Müller JP; Center for Molecular Biomedicine, Institut für Molekulare Zellbiologie, Universitätsklinikum Jena, Jena, Germany.
Zernecke A; Institut für Experimentelle Biomedizin II, Universitätsklinikum Würzburg, Würzburg, Germany.
Hochhaus A; Abteilung für Hämatologie und internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Ernst T; Abteilung für Hämatologie und internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Butt E; Institut für Experimentelle Biomedizin II, Universitätsklinikum Würzburg, Würzburg, Germany.
Frietsch JJ; Abteilung für Hämatologie und internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Źródło:
Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Mar; Vol. 24 (5), pp. 2942-2955. Date of Electronic Publication: 2020 Jan 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
MeSH Terms:
Drug Resistance, Neoplasm*/drug effects
Gene Knockout Techniques*
Adaptor Proteins, Signal Transducing/*metabolism
Cytoskeletal Proteins/*metabolism
LIM Domain Proteins/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*pathology
Protein Kinase Inhibitors/*pharmacology
Receptors, CXCR4/*metabolism
Adenosine Triphosphate/metabolism ; Cell Adhesion/drug effects ; Cell Death/drug effects ; Cell Degranulation/drug effects ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; K562 Cells ; Killer Cells, Natural/drug effects ; Killer Cells, Natural/metabolism ; Killer Cells, Natural/physiology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Protein Biosynthesis/drug effects ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use ; Transcription, Genetic/drug effects ; Treatment Outcome
References:
Bone Marrow Transplant. 2012 Sep;47(9):1171-7. (PMID: 22158386)
Oncogene. 2016 Mar 3;35(9):1122-33. (PMID: 25982273)
Biochim Biophys Acta. 2007 Apr;1768(4):952-63. (PMID: 17169327)
Nucleic Acids Res. 2005 Nov 10;33(20):e175. (PMID: 16284200)
J Cell Biol. 2005 Oct 24;171(2):209-15. (PMID: 16247023)
N Engl J Med. 2017 Mar 9;376(10):917-927. (PMID: 28273028)
Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G37-G44. (PMID: 18483181)
Curr Opin Hematol. 2018 Jan;25(1):44-51. (PMID: 28914666)
Int J Hematol. 2018 Oct;108(4):355-364. (PMID: 28689264)
Blood. 2014 May 22;123(21):3316-26. (PMID: 24705490)
Curr Hematol Malig Rep. 2017 Oct;12(5):495-505. (PMID: 28852963)
Cell. 2013 Sep 12;154(6):1380-9. (PMID: 23992846)
Leukemia. 2012 Mar;26(3):465-74. (PMID: 21904381)
Eur J Cancer. 2013 Mar;49(4):974-83. (PMID: 23084841)
Blood. 2011 Jul 7;118(1):9-18. (PMID: 21562044)
Biochem Pharmacol. 2010 Sep 1;80(5):602-12. (PMID: 20382130)
PLoS One. 2015 Jun 10;10(6):e0129219. (PMID: 26061439)
Nat Med. 2006 Oct;12(10):1175-80. (PMID: 16998483)
PLoS One. 2010 Apr 19;5(4):e10050. (PMID: 20419088)
Oncogene. 2017 Sep 21;36(38):5331-5340. (PMID: 28534514)
Biostatistics. 2003 Apr;4(2):249-64. (PMID: 12925520)
Oncotarget. 2016 Sep 27;7(39):64244-64259. (PMID: 27588391)
Mol Cancer Ther. 2014 May;13(5):1155-69. (PMID: 24502926)
Blood. 2015 Jul 2;126(1):42-9. (PMID: 25918346)
Leukemia. 2007 Mar;21(3):494-504. (PMID: 17252012)
Oncotarget. 2015 Jan 1;6(1):26-42. (PMID: 25622104)
Bioinformatics. 2012 Mar 15;28(6):823-30. (PMID: 22296787)
Mol Cancer Ther. 2008 Jan;7(1):48-58. (PMID: 18202009)
Lancet Oncol. 2010 Nov;11(11):1029-35. (PMID: 20965785)
J Immunol Methods. 2004 Nov;294(1-2):15-22. (PMID: 15604012)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
J Mol Cell Cardiol. 2014 Dec;77:125-35. (PMID: 25451169)
Blood. 2013 Jul 25;122(4):515-22. (PMID: 23704092)
J Cell Mol Med. 2020 Mar;24(5):2942-2955. (PMID: 31957290)
Blood. 2010 Jan 14;115(2):315-25. (PMID: 19837975)
Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix. (PMID: 11147225)
Cancer Res. 2015 Jan 1;75(1):111-9. (PMID: 25385028)
J Cancer Res Clin Oncol. 2018 May;144(5):945-954. (PMID: 29468438)
Front Oncol. 2018 Sep 21;8:391. (PMID: 30298118)
Oncotarget. 2014 Jul 30;5(14):5257-71. (PMID: 24913448)
Curr Hematol Malig Rep. 2010 Apr;5(2):81-7. (PMID: 20425400)
Leukemia. 2016 May;30(5):1044-54. (PMID: 26837842)
Tumour Biol. 2017 Jun;39(6):1010428317705757. (PMID: 28621232)
Blood. 2002 Jan 1;99(1):319-25. (PMID: 11756187)
Br J Cancer. 2010 May 25;102(11):1645-53. (PMID: 20461080)
Contributed Indexing:
Keywords: BCR-ABL; CML; CXCR4; LASP1; nilotinib; precursor cells
Substance Nomenclature:
0 (Adaptor Proteins, Signal Transducing)
0 (CXCR4 protein, human)
0 (Cytoskeletal Proteins)
0 (LASP1 protein, human)
0 (LIM Domain Proteins)
0 (Protein Kinase Inhibitors)
0 (Pyrimidines)
0 (Receptors, CXCR4)
8A1O1M485B (Imatinib Mesylate)
8L70Q75FXE (Adenosine Triphosphate)
F41401512X (nilotinib)
Entry Date(s):
Date Created: 20200121 Date Completed: 20210423 Latest Revision: 20220114
Update Code:
20240104
PubMed Central ID:
PMC7077607
DOI:
10.1111/jcmm.14910
PMID:
31957290
Czasopismo naukowe
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR-ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR-ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1-mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not only overexpression of CXCR4, but also knockout of LASP1 contributes to proliferation, reduced apoptosis and migration as well as increased adhesive potential of K562 CML cells. Furthermore, LASP1 depletion in K562 CML cells leads to decreased cytokine release and reduced NK cell-mediated cytotoxicity towards CML cells. Taken together, these results indicate that in CML, reduced levels of LASP1 alone and in combination with high CXCR4 expression may contribute to TKI resistance.
(© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies